Back to Agenda
Quantitative Benefit-Risk Assessment: What Methods are Being Used? How Far has Industry Come?
Session Chair(s)
Meredith Smith, PhD, MPA, FISPE
Senior Director, Implementation Science Pillar Lead
Evidera, Inc, United States
This session will describe the results of a recently conducted industry-wide survey on the use of quantitative benefit-risk assessment (qBRA) methods within life science companies. In particular, it will describe whether and to what extent such methods are being utilized, what are the types of qBRA methods being utilized, challenges to implementing qBRA within these organizations, and strategies for overcoming those challenges.
Learning Objective : Describe when, why and to what extent qBRA is being adopted within different life science companies to inform decision making; Describe the range of frameworks and methods being utilized within life science companies to implement qBRA; Identify the challenges to introducing qBRA within life science companies and ways that these have been overcome, including factors to facilitate successful implementation.
Speaker(s)
When, Why, and to What Extent qBRA is Being Adopted Within Different Lifescience Companies to Inform Decision Making?
Kevin Marsh, PhD, MSc
Evidera, United Kingdom
Vice President, Patient-Centered Research
What Are the Types of Benefit-Risk Assessment Frameworks Being Used Within the Pharmaceutical Industry Currently and What are the Range of qBRA Methods Being Employed?
Brett Hauber, PhD, MA
Pfizer Inc, United States
Senior Director, Patient Preference Elicitation
What Are the Challenges to Introducing qBRA Within Lifescience Companies and Ways that These Have Been Overcome?
Rachael L. DiSantostefano, PhD, MS
Janssen Research & Development, LLC, United States
Senior Director, Epidemiology
Future Directions for Use of qBRA
Meredith Smith, PhD, MPA, FISPE
Evidera, Inc, United States
Senior Director, Implementation Science Pillar Lead
Have an account?